Newsroom

LAS VEGAS--(BUSINESS WIRE)--Rimini Street, Inc., (Nasdaq: RMNI), dostawca kompleksowego wsparcia w zakresie oprogramowania firmowego, usług zarządzanych i innowacyjnych rozwiązań w zakresie ERP opartych na AI typu agent o zasięgu globalnym, wiodący podmiot zewnętrzny świadczący usługi wsparcia dla oprogramowania Oracle, SAP i VMware, przekazał dzisiaj następującą informację o niedawnym uzyskaniu dodatkowego zwrotu z zaangażowanego kapitału i optymalizacji balansu w trzecim kwartale bieżącego ro...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Innventure, Inc. (“Innventure” or the “Company”) (NASDAQ: INV) and reminds investors of the October 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm...

TOWSON, Md.--(BUSINESS WIRE)--Maryland Council on Economic Education Endorses AP Business with Personal Finance...

NEW YORK--(BUSINESS WIRE)--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission Oil Franchise Tax Senior Revenue Bonds, Series A of 2026 and a long-term rating of A+ to the Commission's Oil Franchise Tax Subordinated Revenue Bonds, Series B of 2026. KBRA additionally affirms the long-term rating of AA- for the Commission's outstanding Oil Franchise Tax Senior Revenue Bonds and A+ for the Commission's outstanding Oil Franchise Tax Subordinated Revenue Bonds. The rating...

拉斯維加斯--(BUSINESS WIRE)--(美國商業資訊)-- 端對端企業軟體支援、託管服務及代理型人工智慧ERP創新解決方案的全球供應商以及Oracle、SAP和VMware軟體的一流支援服務協力廠商Rimini Street, Inc.（Nasdaq: RMNI）今日宣布，在截至2026年8月28日的第三會計季度，近期已採取以下所述的額外資本報酬及資產負債表最佳化措施： 債務削減 ：公司提前償還了500萬美元的定期貸款，本會計年度迄今，定期貸款債務總額已減少2,590萬美元，未償還餘額降至4,340萬美元。 股票回購：公司回購了970,566股普通股，平均回購價格為每股5.16美元，總耗資約500萬美元。 「今年迄今為止的股票回購和債務提前償還彰顯了我們致力於創造長期股東價值的承諾，以及我們在資本配置方面嚴謹務實的態度。」Rimini Street執行副總裁兼財務長Michael Perica表示，「2026會計年度迄今，我們已投入3,090萬美元用於資本報酬及資產負債表最佳化，在提升股東價值、進一步降低債務並鞏固資產負債表的同時，仍保留了投資於策略性成長重點領域所需的財務彈...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectati...

LOS ANGELES--(BUSINESS WIRE)--XTIA Investors Have Opportunity to Lead XTI Aerospace, Inc. Securities Fraud Lawsuit with SBS Law...

SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintain the treatment plans and provider relationships they rely on, n...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus brand to transition to the Hims brand. Australia represents a mean...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scien...